CA-MATTEL
13.11.2021 23:43:12 CET | Business Wire | Press release
The winner of the 2021 Hot Wheels™ Legends Tour was selected today during a global livestream event at Jay Leno’s Garage. Hailing from Somerset, England, the 1969 Volvo P1800 built by Lee Johnstone will join a prestigious group of custom cars in the Hot Wheels Garage of Legends™ and will be forever immortalized as a 1:64 Hot Wheels® die-cast toy.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211113005258/en/
This Volvo P1800 "Aint No Saint" Gasser was originally registered as new in 1969. Its owner, 71-year-old English motor mechanic Lee Johnstone, acquired the vehicle as a rusty rolling shell before thoroughly restoring, modifying, and transforming it into the quarter-mile monster it is today. Sporting a Chevrolet 454 big block, its new power plant is capped with a 671 GMC supercharger and dual four-barrel carburetors. Finished in a fitting shade of Volvo green, it is a true culmination of more than 50 years of ‘race it, break it, build it better’ experience. Perhaps most importantly – and in true challenger spirit – "Aint No Saint" is also a family affair, with Lee's three daughters, Eleanor, Sarah and Victoria, sharing in the driving duties, and his wife, Sue, on standby to help crew.
Finishing its fourth year, the Hot Wheels Legends Tour is a worldwide competition spanning 11 countries and five continents, making it the world’s largest international traveling car show. Thousands of builds were submitted to compete in a series of in-person and virtual stops, which began in April 2021. Over the past seven months, some of the most unique and inspiring custom creations went head-to-head, all for a chance to become the next Hot Wheels die-cast toy sold – and played with by fans of all ages – across the globe.
This year’s global Grand Finale was co-hosted by celebrity car enthusiast Jay Leno and motorsports ambassador Jarod DeAnda during a virtual livestream event, where they were joined by an array of automotive and design experts from around the world to complete the task of choosing the 2021 winner. Joining them on stage were Ted Wu, Global Head of Design for Vehicles, Mattel; Bryan Benedict, Director of Vehicles Design, Mattel; Brendon Vetuskey, Vehicles Designer, Mattel; Henrik Fisker, automotive design icon; Elana Scherr, senior editor of Car and Driver; car customizer and automotive electronics guru Mad Mike; and automotive content creator and drifting enthusiast Sara Choi.
“The Hot Wheels Legends Tour has truly become a global celebration of custom car creations,” said Ted Wu, Vice President, Global Head of Design for Vehicles, Mattel. “With the addition of five new countries in the Tour, we have been able to reach and interact with millions of new fans and builders from around the world. The Volvo Gasser is a wonderful expression of authenticity, creativity and, most importantly, garage spirit. We look forward to welcoming Lee Johnstone and his 1969 Volvo P1800 into the Hot Wheels family and presenting the world with our newest Hot Wheels Legends Tour die-cast toy.”
“Having my family here with me for this moment was so special,” said Lee Johnstone. “I am excited to have my car become a Hot Wheels die-cast toy and to be able to share my passion project in 1:64 scale with the world. It’s amazing to be the first U.K. winner.”
The 2021 Hot Wheels Legends Tour was made possible in collaboration with Walmart and Mobil 1.
To learn more about the Hot Wheels Legends Tour, visit https://hotwheels.mattel.com/explore/en/legends-tour .
ABOUT HOT WHEELS
As a 53-year old brand more relevant today than ever before, Hot Wheels is the world’s leading vehicle franchise which represents and unites all segments of car culture. For decades Hot Wheels has proven its influence in automotive and pop culture with legendary design and epic performance. Through unparalleled collaborations with global leaders in streetwear, fashion, luxury, entertainment, action sports and motorsports, Hot Wheels is the #1 selling toy in the world* with over 8 billion vehicles sold. The brand engages fans of every generation through immersive live events, global competitions, theme park attractions, world-class digital gaming, consumer products and film and television content.
About Mattel
Mattel is a leading global toy company and owner of one of the strongest catalogs of children’s and family entertainment franchises in the world. We create innovative products and experiences that inspire, entertain and develop children through play. We engage consumers through our portfolio of iconic brands, including Barbie®, Hot Wheels®, Fisher-Price®, American Girl®, Thomas & Friends™, UNO® and MEGA®, as well as other popular intellectual properties that we own or license in partnership with global entertainment companies. Our offerings include film and television content, gaming, music and live events. We operate in 35 locations and our products are available in more than 150 countries in collaboration with the world’s leading retail and e-commerce companies. Since its founding in 1945, Mattel is proud to be a trusted partner in empowering children to explore the wonder of childhood and reach their full potential.
About Mobil 1
Mobil 1™ motor oil is the world's leading brand of synthetic motor oil. Our advanced technology allows Mobil 1 motor oils to meet or exceed some of the industry’s toughest standards and to provide exceptional protection under even extreme driving conditions. Mobil 1 motor oil is designed to help protect critical engine parts, maximize engine performance, and extend engine life. For more information, visit us online at www.mobil1.us or and follow @Mobil1 on Facebook, Instagram and Twitter.
*Source: The NPD Group/Retail Tracking Service
MAT-W
View source version on businesswire.com: https://www.businesswire.com/news/home/20211113005258/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom